NCT05328908 2025-08-13
RELATIVITY-123
Bristol-Myers Squibb
Phase 3 Terminated
Clinical Trials
11 trialsNCT05770882 2025-03-11
Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)
Great Novel Therapeutics Biotech & Medicals Corporation
Phase 1/2 Terminated
NCT03563157 2024-12-11
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03555149 2023-11-07
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
Hoffmann-La Roche
Phase 1/2 Terminated
NCT03644511 2020-08-21
SORAGO-HCC
Bayer
Terminated
NCT02425683 2020-02-10
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
US Oncology Research
Phase 2 Terminated
NCT02119676 2018-02-13
Study of Ruxolitinib in Colorectal Cancer Patients
Incyte Corporation
Phase 2 Terminated
NCT02168777 2018-01-26
Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer
Bayer
Phase 1 Terminated
NCT01939223 2017-10-20
COAST
Bayer
Phase 3 Terminated
NCT02287025 2017-10-19
SMART
Bayer
Phase 4 Terminated
NCT01187615 2014-07-08
Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer
Bayer
Phase 1 Terminated